Evaluate the Efficacy and Safety of the Combined Use of a Sodium-glucose Cotransporter 2 (iSGLT2) Inhibitor and a Dipeptidyl Peptidase-4 (iDPP -4) Inhibitor in the Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin

The present study aims to evaluate the efficacy and safety of different combinations of oral antidiabetics in patients with inadequate glycemic control on metformin monotherapy.

Start Date30 Nov 2026

Sponsor / Collaborator

Eurofarma Laboratórios SA

NCT07310433

/ Not yet recruitingPhase 2IIT

Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer: a Phase 2, Multicenter, Open-label, Randomized Controlled Trial

Dapagliflozin is a well-established medication being marketed and used for treatment Type 2 diabetes mellitus (T2DM). In retrospective cohort studies done by our team, we found that metastatic prostate cancer patients who received Dapagliflozin together with standard anti-cancer treatment, androgen deprivation therapy (ADT) combined with novel hormonal agent (NHA), had better tumor control than those having ADT and NHA.

Start Date01 Jun 2026

Sponsor / Collaborator

The University of Hong Kong

[+2]

100 Clinical Results associated with Dapagliflozin

100 Translational Medicine associated with Dapagliflozin

100 Patents (Medical) associated with Dapagliflozin

3,700

Literatures (Medical) associated with Dapagliflozin

01 Dec 2026·JOURNAL OF MOLECULAR MEDICINE-JMM

Dapagliflozin inhibits TGF-β-induced transdifferentiation of valvular interstitial cells and mitral valvular degeneration

Article

Author: Kameshima, Satoshi ; Sakai, Kosei ; Sato, Remi

Abstract:

Myxomatous mitral valve (MV) disease (MMVD) is a common cardiac condition in humans and dogs. Currently, no therapeutic agent is available for MMVD that can prevent MV degeneration. Transforming growth factor (TGF)-β-induced transdifferentiation of valvular interstitial cells (VICs) is a key process in MV degeneration. Dapagliflozin is used to treat type 2 diabetes, and it alleviates cardiac and renal fibrosis by inhibiting the TGF-β signaling pathway. In this study, we investigated the effect of dapagliflozin on TGF-β-induced transdifferentiation of VICs and MV degeneration in rats. Protein expression levels and contractile forces generated by VICs were determined using western blotting and a collagen gel contraction assay, respectively. Structural changes of the MV were detected using histological staining. Dapagliflozin inhibited TGF-β-induced Smad2/3 phosphorylation and increased alpha-smooth muscle actin expression and the cellular contractile force. In contrast, dapagliflozin increased the activity of adenosine monophosphate-activated protein kinase (AMPK)α. However, 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside, an AMPK activator, inhibited TGF-β-induced Smad2/3 phosphorylation. AMPKα gene knockdown impeded the inhibitory effect exerted by dapagliflozin on TGF-β-induced Smad2 phosphorylation. Additionally, dapagliflozin increased AMPKα phosphorylation and suppressed TGF-β-induced MV degeneration, alpha-smooth muscle actin expression, and Smad2/3 phosphorylation in isolated rat MV. To the best of our knowledge, this study is the first to demonstrate that dapagliflozin inhibits TGF-β-induced VIC differentiation and subsequent MV degeneration by suppressing Smad signaling via AMPK activation, suggesting that dapagliflozin is a potential novel therapeutic agent for MMVD.

Key messages:

TGF-β-induced VIC differentiation leads to MV degeneration.DAPA, an SGLT2 inhibitor, suppresses the TGF-β signaling pathway.DAPA inhibits TGF-β-induced differentiation of rat VIC via AMPK activation.DAPA inhibits TGF-β-induced degeneration and signal transduction in isolated rat MV.DAPA suppresses MV degeneration by inhibiting VIC differentiation.

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Dapagliflozin attenuates hypothyroidism induced liver and lung dysfunction via regulation of mitophagy and apoptosis

Article

Author: Ahmed, Manar Fouad ; Mohammed, Marwa Abdeltawab ; Eweda, Sarah A ; Ali, Esraa Mohamed ; Abdelrahim, Dina Sayed ; Mohammed, Maha Tarek

BACKGROUND:

Thyroid hormones are mainly concerning with regulation of organs metabolism. Hypothyroidism is a pathological condition characterized by decrease of T3 and T4 level that negatively impact various organs especially liver and lung. Dapagliflozin (DAPA) is an anti diabetic drug posses antioxidant and anti apoptotic properties AIM OF THE STUDY: The aim of this work is to identify the effect of DAPA on disturbance of liver and lung functions result from hypothyroidism MATERIALS AND METHODS: Twenty four rats (6 rats/group) were divided into four groups: control group, DAPA group that received DAPA (1 mg/kg/day for five weeks), PTU group that received propylthiouracil (15 mg/kg/day for five weeks), PTU+ DAPA group that received PTU and DAPA as described in the other groups RESULTS: Hypothyroidism induced oxidative stress associated mitophagy disturbance in both lung and liver with development of apoptosis in liver. DAPA avoided this effect CONCLUSION: DAPA protects against liver and lung injury result from hypothyroidism.

01 Apr 2026·BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Dapagliflozin targets RORγt to improve myocardial ischemia-reperfusion injury-induced heart failure by regulating the CD4+ T cell/Th17 cell axis within cardiac tissue

Article

Author: Gao, Shan ; Ge, Fei ; Ge, Xuewan ; Guo, Anping ; Xu, Ming ; Liao, Yufeng ; Shi, Tianlu ; Cai, Weiwei ; Song, Wei ; Lu, Yao ; Huang, Lei ; Luo, Qichao ; Wu, Yaqin ; Yu, Dongbiao ; Wu, Yan ; Shi, Chao

Dapagliflozin (DAPA) is the first sodium-glucose cotransporter 2 (SGLT2) inhibitor to receive approval for clinical use in China. However, the mechanism behind the cardioprotective effects of DAPA remains unclear, as cardiac tissue does not express SGLT2. This study investigated the efficacy of DAPA in alleviating myocardial ischemia-reperfusion (MIR) injury, independent of its glucose-lowering properties. The findings revealed that DAPA significantly improved cardiac function and decreased ventricular remodeling in a murine model of MIR injury-induced heart failure (HF). Furthermore, bioinformatics and cellular thermal shift assays (CETSAs) revealed that retinoid-related orphan receptor gamma t (RORγt) acts as a specific molecular target. Moreover, DAPA alleviated MIR injury-induced increased cardiac CD4⁺ T cells as well as RORγt, interleukin-17 A (IL-17 A), and CD4 levels in cardiac tissue. This immunomodulatory effect was clinically significant, as proportions of peripheral blood T helper 17 (Th17) cells were significantly decreased in post-acute myocardial infarction (post-AMI) HF patients undergoing DAPA therapy. In conclusion, the study investigated the cardioprotective effects of DAPA, demonstrating that it can modulate the cardiac immune micro-environment via RORγt, which regulates the CD4⁺ T cell/Th17 cell axis within cardiac tissue. These findings offer mechanistic validation for the tissue-specific therapeutic effects of DAPA in the heart, establishing pharmacological regulation of immune metabolic pathways as an innovative precision medicine strategy for HF, and highlighting its translational potential.

361

News (Medical) associated with Dapagliflozin

25 Feb 2026

·www.prnewswire.com

Barshop Institute to receive up to $38 million from ARPA-H, anchoring UT San Antonio as a national leader in aging and healthy longevity science

SAN ANTONIO, Feb. 24, 2026 /PRNewswire/ -- Positioning The University of Texas at San Antonio as a national anchor for aging and longevity science, its Sam and Ann Barshop Institute for Longevity and Aging Studies will receive up to $38 million in federal funding for the first nationwide clinical study in healthy longevity. The Advanced Research Projects Agency for Health (ARPA-H), an agency of the U.S. Department of Health and Human Services, announced the contract to the Barshop Institute at UT Health San Antonio, the academic health center of UT San Antonio, cementing its standing as the nation's leading authority in longevity science. The first-of-its-kind study will evaluate the repurposing of FDA-approved medications to delay age-related health and functional decline in generally healthy middle-aged adults, ages 60 to 65. The contract will support the Validation and Intervention Testing for Aging, Longevity and Healthspan (VITAL-H) trial, which is integrated into the ARPA-H Proactive Solutions for Prolonging Resilience (PROSPR) program. Specifically, the Barshop Institute will use the VITAL-H trial to study the medications rapamycin, dapagliflozin and semaglutide, which based on strong preclinical evidence, promising early human data and extensive post-marketing safety experience may positively affect age-related decline in quality of life and lifespan. "PROSPR is designed to identify therapeutics that show the aging process is not an inevitable slide into disability," said Andrew Brack, ARPA-H program manager and creator of the PROSPR program. "VITAL-H will help show whether we can preserve everyday abilities during a critical window of midlife aging." For the Barshop Institute, it is the culmination of decades of pioneering biomedical science, a national vote of confidence and a proven model to translate aging research into real-world clinical impact. And it is further evidence of UT San Antonio's growing national research standing, providing a platform for the next decade of leadership in aging science. "For decades, the Barshop Institute has helped define the biology of aging," said Jennifer Sharpe Potter, PhD, MPH, senior executive vice president for research and innovation for UT San Antonio. "Today, that foundational science has matured into a national clinical research effort – led from San Antonio – that will shape the future of human health and longevity." Barshop Institute director Elena Volpi, MD, PhD, who along with her team of investigators are nationally recognized leaders in healthy longevity research, will head the new effort. "Over the past 50 years, global life expectancy has increased substantially, yet the age of onset of age-related diseases and disabilities has remained largely unchanged," Volpi said. "Our population is living longer but with declining function, increased disability and reduced quality of life with major implications for healthcare utilization, caregiver burden and societal costs. Despite major advances in the biology of aging, no FDA-approved interventions currently exist to delay the onset of age-related functional decline or preserve health span in otherwise healthy adults. "This work is focused on changing that trajectory," she said, "advancing science that can help people live not just longer lives, but healthier ones in the decades ahead." The PROSPR program is intended to identify biochemical and physiological markers and develop assessment tools that allow researchers to better understand and target the underlying causes of age-related disease and build interventions focused on maintaining health during aging. The FDA-approved rapamycin, dapagliflozin and semaglutide medications all have distinct mechanisms of action, are orally administered and have favorable safety profiles at low doses, enabling long-term use in generally healthy populations. The trial is designed to deliver evidence on whether repurposed, FDA-approved drugs can slow age-related decline in generally healthy older adults as well as provide the first large-scale validation of Intrinsic Capacity, which is the concept for healthy aging addressing a person's physical and mental capabilities. Intrinsic Capacity is evaluated by testing cognition, mobility (locomotor), psychological, vitality and sensory functions, to gauge health in aging individuals. The VITAL-H trial will use wearable technologies to monitor the study population selected to capture a critical window in which functional decline is measurable, yet disease burden remains relatively low. Participants will be recruited from South Texas, a region with a demographic makeup that closely mirrors the projected U.S. population in the coming decades, making the results relevant to our country's future population aging. "By reframing aging as a modifiable functional trajectory rather than an inevitable accumulation of disease, the study establishes a scalable, regulatory-grade framework for preventive interventions that could possibly inform future clinical development and positively affect people's lives as they age," Volpi said. Clinical trials targeting aging have previously focused on treatment after disease onset, are often underpowered, and rely on narrow or single-modality clinic-based outcomes that limit sensitivity, generalizability and scalability. The VITAL-H clinical trial is designed to evaluate aging interventions earlier in the life course using endpoints capable of detecting meaningful functional change within feasible timeframes. While the award will be centered at the Barshop Institute, located in the San Antonio Medical Center, there will be multiple partner locations throughout the city. Regional locations and partners will include the San Antonio Geriatric Research, Clinical and Research Center (GRECC); the South Texas Veterans Health Care System (STVHCS); the Texas Diabetes Institute (TDI); the West San Antonio Food Bank (SAFB); and a UT Health San Antonio mobile clinical research clinic. For more information on the VITAL-H Trial, visit the Barshop Institute Current Clinical Trials website at: This research was, in part, funded by the Advanced Research Projects Agency for Health (ARPA-H). The views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the United States Government. The Sam and Ann Barshop Institute for Longevity and Aging Studies at UT Health San Antonio is one of the world's premier institutes dedicated to the study of age-related diseases. The Barshop Institute is the only aging-intensive research institute in the country to have five peer-reviewed designations: three National Institute on Aging (NIA)-funded centers (Nathan Shock, Claude D. Pepper, and Population Aging and Social Studies centers), a lead site of the NIA-sponsored Interventions Testing Program, and a U.S. Department of Veterans Affairs Geriatric Research, Education and Clinical Center. UT Health San Antonio is the academic health center of The University of Texas at San Antonio (UT San Antonio). SOURCE UT Health San Antonio 21% more press release views with Request a Demo

Drug ApprovalClinical Study

12 Feb 2026

·firstwordpharma.com

Blockbuster ambitions grow as AstraZeneca moves oral GLP-1 into pivotal studies

AstraZeneca is moving its oral, once-daily GLP-1 receptor agonist elecoglipron (AZD5004) into Phase III development for obesity and type 2 diabetes in the hopes of adding another drug to its growing portfolio of blockbusters. The company — alongside announcing its latest financial results on Tuesday — noted that it currently has 16 blockbuster medicines on its hands and is hoping to expand this to over 25 by the end of the decade. In 2024, when AstraZeneca set out its target of growing annual revenue to $80 billion by 2030, the drugmaker had 12 blockbusters in its portfolio. "The momentum across our company is continuing in 2026 and we are looking forward to the results of more than 20 Phase III trial readouts this year," said CEO Pascal Soriot. The decision to advance elecoglipron — in-licensed from Eccogene in 2023 — follows positive results from the Phase IIb VISTA and SOLSTICE studies, which evaluated the drug in obesity and type 2 diabetes, respectively. AstraZeneca disclosed Tuesday that VISTA met its primary endpoints of change in body weight from baseline at 26 weeks and proportion of participants with weight loss ≥5% from baseline weight at 26 weeks. Meanwhile, SOLSTICE also hit its main goal of change in HbA1c from baseline at 26 weeks. Full results from both will be presented at the American Diabetes Association (ADA) scientific sessions in June. "We have a very broad pipeline of Phase III studies that will start" for elecoglipron, Soriot said, with plans to also "combine it with our broader portfolio of agents." The executive picked out the "tremendous opportunity" of combining elecoglipron with its SGLT2 inhibitor Farxiga. "Those two products have benefits not only on the metabolic status of a person, of a patient, but also protecting the kidney, the heart. And we believe this combination will have tremendous impact on the well-being, the health, the general health of people moving forward." Having delivered 16 positive Phase III read outs last year, AstraZeneca indicated that it has more than 100 ongoing late-stage trials, with over 20 expected to report results in 2026. Soriot noted that "a substantial and growing number" of these feature "transformative technologies, which have the potential to revolutionise outcomes for patients and drive our growth well beyond 2030." For the current year, AstraZeneca forecasts a mid-to-high single-digit percentage increase in revenue, with core earnings per share growing by a low double-digit percentage. Last year, the company's sales climbed 9% to $58.7 billion, as profit jumped 45% to $10.2 billion. Emerging market growth While countries outside of the US and Europe have long been a focus for AstraZeneca, with China in particular making up a large chunk of the company's sales, it is now other emerging markets that are growing. In 2025, while revenue in China rose 4% to $6.6 billion, growth in other emerging markets reached 19%, bringing in $8.6 billion. "The US...remains our largest geography with 43% of our product revenue. Europe is doing well, but really the highlight is the growth in the emerging markets, in particular outside of China," Soriot said. "This is really one of the strengths of this company. Our broad geographical footprint and in particular our ability to grow in many of these countries around the world where most of the population on the planet live." Chief Financial Officer Aradhana Sarin said that Latin America, Middle East and Africa, Asia all delivered double-digit growth in 2025, which is expected to continue. "And the growth is driven across our therapy areas. So you will see a great performance and strong launches in oncology, particularly with Enhertu and the new indication of Imfinzi," Sarin added. In the final quarter of 2025, growth in emerging markets outside of China was even higher, up 28% to $2.3 billion. AstraZeneca's overall sales in the three-month period climbed 4% to $15.5 billion, with oncology products accounting for $7 billion of this, up 11% year-on-year. Meanwhile, profit surged 55% to $2.3 billion. The content above comes from the network. if any infringement, please contact us to modify.

Clinical Result

10 Feb 2026

·www.fiercepharma.com

AstraZeneca sets sights on 25+ blockbusters by 2030 to fuel $80B revenue ambition

With more than 100 ongoing phase 3 trials and over 20 late-stage readouts slated for 2026, AstraZeneca is entering an “unprecedented catalyst-rich period,” CEO Pascal Soriot said. After ending 2025 with a strong fourth quarter, AstraZeneca management has doubled down on its ambitious “$80 billion by 2030” revenue target, outlining a roadmap to have more than 25 blockbuster medicines by the end of the decade.During AZ’s Q4 earnings call, CEO Pascal Soriot highlighted an “unprecedented catalyst-rich period.” With more than 100 ongoing phase 3 trials and over 20 late-stage readouts slated for 2026, AZ’s exec team used a big chunk of their time on the call taking inventory of key clinical programs.That large portfolio shows the value of diversification, again highlighting what Soriot called “low concentration risk.”“It’s great to have one or two big products. [It] makes you very profitable and makes you look good,” Soriot said. “But if you lose one of those, as we’ve seen happen to some actors in the industry lately, it really becomes very painful, very quickly. So this diversification, both product-wise, but also geographically, is suddenly becoming more apparent as we drive growth through therapy areas but also through regions.”AZ capped 2025 with fourth-quarter revenues of $15.5 billion, which arrived slightly above analysts’ expectations, thanks mainly to the company's oncology portfolio.But rather than commercial performance, analysts on Tuesday’s call were heavily focused on AZ’s clinical programs, wondering whether the British pharma can repeat the level of phase 3 successes it enjoyed last year.Among key 2026 readouts at the top of AZ’s—and investors’—minds are: Avanzar evaluating Daiichi Sankyo-partnered Datroway in first-line non-small cell lung cancer; Serena-4 for the oral SERD camizestrant in first-line HR-positive breast cancer; CardioTTRansform testing Ionis-partnered Wainua in transthyretin amyloid cardiomyopathy; three phase 3 trials of efzimfotase alpha in the rare metabolic bone disease hypophosphatasia; and three phase 3 studies of the IL-33 agent tozorakimab in chronic obstructive pulmonary disease (COPD). Avanzar represents the epitome of AZ’s recent efforts to help improve the probability of success of its clinical studies. With the help of artificial intelligence, the company developed a new TROP2-based biomarker in the hopes of enriching for responders to Datroway. In April 2025, AZ signed a three-way deal with Tempus AI and Pathos AI to construct a patient data-based multimodal oncology model.“My reflection of the last decade in oncology, about the success rates we’ve had, has been predicated on being able to identify the right patient populations to treat,” AZ’s oncology R&D head, Susan Galbraith, Ph.D., said on Tuesday’s call.AZ has been using real-world evidence to help design its phase 3 trials and predict control-arm performance. The hope is that AI models can help in the same way when historical literature data are lacking in certain new biomarker areas or where the biology is more complicated, Galbraith said.As for camizestrant, industry watchers are eager to see results from AZ’s first-line Serena-4 trial and the phase 3 Cambria-1 and -2 studies in early breast cancer, after Roche reported positive data for its rival oral SERD, giredestrant, in two similar settings. The key focus is if oral SERDs can break into an earlier and larger population beyond patients whose tumors have ESR1 mutations.For the first-line trial, AZ has designed the study to enrich for endocrine-sensitive patients, who are expected to respond better to oral SERDs, Galbraith said. Those patients typically experienced recurrence from early-stage disease after at least two years of standard adjuvant therapy because those that are less endocrine-sensitive typically progress more rapidly, she explained.In the adjuvant setting, the two studies target different patient populations that could potentially give AZ access to the largest group of patients, Galbraith said. While Cambria-1 allows patients to have used a CDK4/6 inhibitor, Cambria-2 allows concurrent use of a CDK4/6 inhibitor, which Galbraith said is important now that these meds are becoming the new standard in the adjuvant setting.Outside of oncology, as one analyst noted on Tuesday’s call, AZ has billed efzimfotase alpha as having the opportunity to reach $3 billion to $5 billion in peak sales. The drug’s once-every-other-week dosing is considered an upgrade from the up to once-every-two-days frequency of AZ’s Strensiq.With three phase 3 trials, AZ’s goal is again for the newer enzyme therapy to reach a broad population, Marc Dunoyer, CEO of AZ’s rare disease unit, Alexion, said on the call. Two trials are in the pediatric population—one in which patients switch from Strensiq and the other in Strensiq-naïve patients—and the third trial combines adolescents and adults.In the biopharmaceutical department, AZ is targeting the very competitive ATTR-CM field. As the largest trial in this disease, CardioTTRansform is powered to run a key subgroup analysis among patients who are on baseline treatment with Pfizer’s Vyndamax. Information here is important because it may change treatment guidelines, Sharon Barr, Ph.D., AZ’s head of biopharmaceuticals R&D, said on the call. A big question for AZ’s biopharmaceutical business is whether the company can sustain the blow from the loss of exclusivity of its SGLT-2 inhibitor Farxiga, which generated $8.4 billion in sales in 2025. The drug was also one of the first drugs selected for price negotiations under the Inflation Reduction Act, with a discount for Medicare taking effect at the beginning of this year.AZ’s biopharmaceutical business will “have a blip” following the Farxiga patent cliff, but the company has enough other growth drivers, Ruud Dobber, who leads the unit, said on the call.He pointed to the potential 2026 launch of baxdrostat for hard-to-control hypertension, noting that AZ has set the drug’s overall peak sales potential above $5 billion. Respiratory and immunology drugs Breztri and Tezspire are also expected to continue their double-digit growth, he said.

Phase 3Phase 2

100 Deals associated with Dapagliflozin

External Link

KEGG	Wiki	ATC	Drug Bank
D09763	Dapagliflozin	A10BK01	DB06292

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 1	Japan	AstraZeneca Pharmaceuticals Co. Ltd.	26 Mar 2019
Chronic heart failure	European Union	AstraZeneca AB	11 Nov 2012
Chronic heart failure	Iceland	AstraZeneca AB	11 Nov 2012
Chronic heart failure	Liechtenstein	AstraZeneca AB	11 Nov 2012
Chronic heart failure	Norway	AstraZeneca AB	11 Nov 2012
Chronic Kidney Diseases	Australia	AstraZeneca Pty Ltd.	22 Oct 2012
Diabetes Mellitus, Type 2	Australia	AstraZeneca Pty Ltd.	22 Oct 2012
Heart Failure	Australia	AstraZeneca Pty Ltd.	22 Oct 2012

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute myocardial infarction	Phase 3	Sweden	AstraZeneca PLC	22 Dec 2020
Acute myocardial infarction	Phase 3	United Kingdom	AstraZeneca PLC	22 Dec 2020
Acute Q wave myocardial infarction	Phase 3	Sweden	AstraZeneca PLC	22 Dec 2020
Acute Q wave myocardial infarction	Phase 3	United Kingdom	AstraZeneca PLC	22 Dec 2020
Acute decompensated heart failure	Phase 3	United States	AstraZeneca PLC	01 Apr 2020
Dyspnea, Paroxysmal	Phase 3	United States	AstraZeneca PLC	01 Apr 2020
Heart failure with reduced ejection fraction	Phase 3	United States	AstraZeneca PLC	09 Apr 2019
Heart failure with reduced ejection fraction	Phase 3	Japan	AstraZeneca PLC	09 Apr 2019
Heart failure with reduced ejection fraction	Phase 3	Brazil	AstraZeneca PLC	09 Apr 2019
Heart failure with reduced ejection fraction	Phase 3	Canada	AstraZeneca PLC	09 Apr 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05139914 (SFRNDM2, CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Endothelial dysfunction	4	Placebo+Dapagliflozin (Dapagliflozin Then Placebo)	ikytxwbwlb(skmxwelzry) = vxjnertdms lphkmepxrf (xbszxslcyj, oxrzyoeuez - tcpabneyma) View more	-	11 Feb 2026
				Placebo+Dapagliflozin (Placebo Then Dapagliflozin)	ikytxwbwlb(skmxwelzry) = qluutupeah lphkmepxrf (xbszxslcyj, royptqpkty - ttemxlkynk) View more
NCT03782259 (Pubmed \| Obesity (Silver Spring))	Phase 3	Diabetes Mellitus, Type 2	56	Dapagliflozin 10 mg	-	Positive	02 Feb 2026
				Placebo	hhnrgbieve(qidpmgqpyi) = ixxcyoslty whqxdpynhi (xbnxejjnbp ) View more
NCT06263673 (CTgov)	Phase 4	Lewy Body Disease \| Parkinson Disease	18	Sitagliptin (Sitagliptin Group)	kbtaoiwgua(djvsdjrdrt) = jmrvnvnfee noirvptfvg (evzdlptviy, fbmwywygsf - bldfhcksye) View more	-	28 Jan 2026
				Dapagliflozin (Dapagliflozin Group)	kbtaoiwgua(djvsdjrdrt) = ewxumaakem noirvptfvg (evzdlptviy, pogtuokkqo - zzeqqqetgi) View more
NCT06269484 (ZEAL UNLOCK, CTgov)	Phase 2	Fibrosis \| Liver Cirrhosis \| Compensated cirrhosis	73	Zibo+Dapa (Zibo/Dapa)	ifosrufxfj = hvujbknmnq pbqoietmjc (vfbeeqotsu, vljdkwguzp - jbxostlgxv) View more	-	20 Jan 2026
				placebo+Zibotentan (Zibo)	ifosrufxfj = bdmrsrgxxi pbqoietmjc (vfbeeqotsu, qvccnjutxd - nimufdgigf) View more
NCT04965935 (Pubmed \| Clin J Am Soc Nephrol)	Phase 2	Diabetes Mellitus, Type 2 \| Hypertension	52	Dapagliflozin 10 mg	bxszudqmrk(zveduzyodv) = vubythhpmm uusctdmqqg (tkvdsgsggf, -7.14 to -1.24)	Positive	12 Dec 2025
NCT01730534 (DECLARE-TIMI 58, Pubmed \| ESC Heart Fail)	Phase 3	Diabetes Mellitus, Type 2 Gal-3	14,530	Dapagliflozin	vltxiirorm(ocsjuknnaj) = abkahbjjhx zmaxtbmpxe (sqprrhfsuy, 11.9 - 18.4)	Positive	01 Dec 2025
NCT03982381 (SMARTEST, Pubmed \| Diabetes Obes Metab)	Phase 4	Diabetes Mellitus, Type 2	2,072	Dapagliflozin 10 mg/day	soiossxaio(zzyggrxqcf) = pjxswocqae cfkggwoetk (mebxqbfxji ) View more	Positive	28 Nov 2025
NCT06350123 (MIRO-CKD, Pubmed \| Nephrol Dial Transplant)	Phase 2	Chronic Kidney Diseases	324	Balcinrenone/Dapagliflozin 15 mg/10 mg	gsnyldcwqa(jdmimjkuzr) = vzqrjmkveg tcwvtizkud (yctjizwkho )	Positive	26 Nov 2025
NCT04363697 (DAPA ACT HF-TIMI 68, Pubmed \| Circulation)	Phase 3	Heart Failure	2,401	Dapagliflozin 10 mg	bqztoilkqy(eokixhfxrf) = wfzlbqkcez ihyyysgdfh (dpkthbgytt ) View more	Negative	18 Nov 2025
				Placebo	bqztoilkqy(eokixhfxrf) = wohmoifike ihyyysgdfh (dpkthbgytt ) View more
NCT04724837 (ZENITH-CKD, ASN2025) Manual	Phase 2	Chronic Kidney Diseases	368	Dapagliflozin 10 mg	nyskjoccag(cbcdxqsjdj) = docucteiyg invvvapyjh (vdbluwgfpm, -9.54， - 0.44) View more	Positive	08 Nov 2025
				Zibotentan (0.25 mg or 1.5 mg) + Dapagliflozin 10 mg	nyskjoccag(cbcdxqsjdj) = lntyvoqxgx invvvapyjh (vdbluwgfpm, -17.17， - 9.45) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis